 | • レポートコード：MRC2-11QY11052 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は胆管癌治療のグローバル市場について調査・分析したレポートです。種類別（薬物療法、放射線療法、手術）市場規模、用途別（肝内胆管がん、肝外胆管がん）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別胆管癌治療の競争状況、市場シェア ・世界の胆管癌治療市場：種類別市場規模 2015年-2020年（薬物療法、放射線療法、手術） ・世界の胆管癌治療市場：種類別市場規模予測 2021年-2026年（薬物療法、放射線療法、手術） ・世界の胆管癌治療市場：用途別市場規模 2015年-2020年（肝内胆管がん、肝外胆管がん） ・世界の胆管癌治療市場：用途別市場規模予測 2021年-2026年（肝内胆管がん、肝外胆管がん） ・北米の胆管癌治療市場分析：米国、カナダ ・ヨーロッパの胆管癌治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの胆管癌治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の胆管癌治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの胆管癌治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Accord Healthcare、Bristol-Myers Squibb Company、Celgene Corporation、Delcath Systems、Eli Lilly and Company、F. Hoffman-La Roche、Fresenius Kabi、Johnson & Johnson Services、Kyowa Hakko Kirin、Mylan、Novartis、Pfizer、Sanofi、Teva Pharmaceuticals Industries ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Bile duct is a network of tube that connects the liver to the gall bladder. Bile duct carries a fluid called bile which is synthesize in the liver and stored in the gall bladder. The primary function of bile is breakdown of fats during digestion. Bile duct cancer is commonly known as cholangiocarcinoma. The particular cause of bile duct cancer is unknown but few factors that are responsible for developing bile duct cancer are long-term inflammation in the liver, biliary stones, abnormalities in bile duct such as cysts, infection with liver flukes parasite that causes infection in bile duct leading to cancer, and exposure to harmful chemicals and toxins. Major symptoms associated with bile duct cancer includes jaundice, weight loss, loss of appetite, discoloration of urine and stool, abdominal pain, itching, and fever.
The industrialization in developing counters such as India, China, and other ASEAN countries led to increased exposure to harmful chemicals that are affecting the workers and leading to growth in the incidence of bile duct cancer among the industrial workforce, which is expected to drive market growth positively over the forecast period. Moreover, growing number of drugs has been awarded Orphan drug designation, which also expected to increase the market access and product demand across the globe and leading to lucrative market opportunities for the players in the market.
Market Analysis and Insights: Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
The global Bile Duct Cancer (Cholangiocarcinoma) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Scope and Market Size
Bile Duct Cancer (Cholangiocarcinoma) Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Bile Duct Cancer (Cholangiocarcinoma) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Accord Healthcare
Bristol-Myers Squibb Company
Celgene Corporation
Delcath Systems
Eli Lilly and Company
F. Hoffman-La Roche
Fresenius Kabi
Johnson & Johnson Services
Kyowa Hakko Kirin
Mylan
Novartis
Pfizer
Sanofi
Teva Pharmaceuticals Industries
Market segment by Type, the product can be split into
Drug Therapy
Radiation Therapy
Surgery
Market segment by Application, split into
Intrahepatic Bile Duct Cancer
Extrahepatic Bile Duct Cancer
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue
1.4 Market by Type
1.4.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Drug Therapy
1.4.3 Radiation Therapy
1.4.4 Surgery
1.5 Market by Application
1.5.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application: 2020 VS 2026
1.5.2 Intrahepatic Bile Duct Cancer
1.5.3 Extrahepatic Bile Duct Cancer
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Perspective (2015-2026)
2.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Growth Trends by Regions
2.2.1 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Bile Duct Cancer (Cholangiocarcinoma) Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Market Size
3.1.1 Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Revenue (2015-2020)
3.1.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Concentration Ratio
3.2.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue in 2019
3.3 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players Head office and Area Served
3.4 Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Product Solution and Service
3.5 Date of Enter into Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Historic Market Size by Type (2015-2020)
4.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
5.2 Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
6.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in North America (2019-2020)
6.3 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
6.4 North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
7.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in Europe (2019-2020)
7.3 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
7.4 Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
8 China
8.1 China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
8.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in China (2019-2020)
8.3 China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
8.4 China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
9.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in Japan (2019-2020)
9.3 Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
9.4 Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
10.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
11 India
11.1 India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
11.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in India (2019-2020)
11.3 India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
11.4 India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size (2015-2020)
12.2 Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020)
12.4 Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Accord Healthcare
13.1.1 Accord Healthcare Company Details
13.1.2 Accord Healthcare Business Overview
13.1.3 Accord Healthcare Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.1.4 Accord Healthcare Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020))
13.1.5 Accord Healthcare Recent Development
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Details
13.2.2 Bristol-Myers Squibb Company Business Overview
13.2.3 Bristol-Myers Squibb Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.2.4 Bristol-Myers Squibb Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.2.5 Bristol-Myers Squibb Company Recent Development
13.3 Celgene Corporation
13.3.1 Celgene Corporation Company Details
13.3.2 Celgene Corporation Business Overview
13.3.3 Celgene Corporation Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.3.4 Celgene Corporation Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.3.5 Celgene Corporation Recent Development
13.4 Delcath Systems
13.4.1 Delcath Systems Company Details
13.4.2 Delcath Systems Business Overview
13.4.3 Delcath Systems Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.4.4 Delcath Systems Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.4.5 Delcath Systems Recent Development
13.5 Eli Lilly and Company
13.5.1 Eli Lilly and Company Company Details
13.5.2 Eli Lilly and Company Business Overview
13.5.3 Eli Lilly and Company Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.5.4 Eli Lilly and Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.5.5 Eli Lilly and Company Recent Development
13.6 F. Hoffman-La Roche
13.6.1 F. Hoffman-La Roche Company Details
13.6.2 F. Hoffman-La Roche Business Overview
13.6.3 F. Hoffman-La Roche Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.6.4 F. Hoffman-La Roche Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.6.5 F. Hoffman-La Roche Recent Development
13.7 Fresenius Kabi
13.7.1 Fresenius Kabi Company Details
13.7.2 Fresenius Kabi Business Overview
13.7.3 Fresenius Kabi Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.7.4 Fresenius Kabi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.7.5 Fresenius Kabi Recent Development
13.8 Johnson & Johnson Services
13.8.1 Johnson & Johnson Services Company Details
13.8.2 Johnson & Johnson Services Business Overview
13.8.3 Johnson & Johnson Services Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.8.4 Johnson & Johnson Services Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.8.5 Johnson & Johnson Services Recent Development
13.9 Kyowa Hakko Kirin
13.9.1 Kyowa Hakko Kirin Company Details
13.9.2 Kyowa Hakko Kirin Business Overview
13.9.3 Kyowa Hakko Kirin Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.9.4 Kyowa Hakko Kirin Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.9.5 Kyowa Hakko Kirin Recent Development
13.10 Mylan
13.10.1 Mylan Company Details
13.10.2 Mylan Business Overview
13.10.3 Mylan Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
13.10.4 Mylan Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
13.10.5 Mylan Recent Development
13.11 Novartis
10.11.1 Novartis Company Details
10.11.2 Novartis Business Overview
10.11.3 Novartis Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
10.11.4 Novartis Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
10.11.5 Novartis Recent Development
13.12 Pfizer
10.12.1 Pfizer Company Details
10.12.2 Pfizer Business Overview
10.12.3 Pfizer Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
10.12.4 Pfizer Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
10.12.5 Pfizer Recent Development
13.13 Sanofi
10.13.1 Sanofi Company Details
10.13.2 Sanofi Business Overview
10.13.3 Sanofi Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
10.13.4 Sanofi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
10.13.5 Sanofi Recent Development
13.14 Teva Pharmaceuticals Industries
10.14.1 Teva Pharmaceuticals Industries Company Details
10.14.2 Teva Pharmaceuticals Industries Business Overview
10.14.3 Teva Pharmaceuticals Industries Bile Duct Cancer (Cholangiocarcinoma) Treatment Introduction
10.14.4 Teva Pharmaceuticals Industries Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020)
10.14.5 Teva Pharmaceuticals Industries Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Bile Duct Cancer (Cholangiocarcinoma) Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue
Table 3. Ranking of Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Drug Therapy
Table 6. Key Players of Radiation Therapy
Table 7. Key Players of Surgery
Table 8. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2015-2020)
Table 12. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Growth Strategy
Table 18. Main Points Interviewed from Key Bile Duct Cancer (Cholangiocarcinoma) Treatment Players
Table 19. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue by Players (2015-2020) (Million US$)
Table 20. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Players (2015-2020)
Table 21. Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment as of 2019)
Table 22. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Product Solution and Service
Table 25. Date of Enter into Bile Duct Cancer (Cholangiocarcinoma) Treatment Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 28. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Share by Type (2015-2020)
Table 29. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue Market Share by Type (2021-2026)
Table 30. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Share by Application (2015-2020)
Table 31. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 32. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size Share by Application (2021-2026)
Table 33. North America Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 35. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 36. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 37. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 38. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 39. Europe Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 41. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 43. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 45. China Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 46. China Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 47. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 48. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 49. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 50. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 51. Japan Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 53. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 55. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 59. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 61. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 63. India Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 64. India Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 65. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 66. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 67. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 68. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share (2019-2020)
Table 71. Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type (2015-2020)
Table 73. Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application (2015-2020)
Table 75. Accord Healthcare Company Details
Table 76. Accord Healthcare Business Overview
Table 77. Accord Healthcare Product
Table 78. Accord Healthcare Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 79. Accord Healthcare Recent Development
Table 80. Bristol-Myers Squibb Company Company Details
Table 81. Bristol-Myers Squibb Company Business Overview
Table 82. Bristol-Myers Squibb Company Product
Table 83. Bristol-Myers Squibb Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 84. Bristol-Myers Squibb Company Recent Development
Table 85. Celgene Corporation Company Details
Table 86. Celgene Corporation Business Overview
Table 87. Celgene Corporation Product
Table 88. Celgene Corporation Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 89. Celgene Corporation Recent Development
Table 90. Delcath Systems Company Details
Table 91. Delcath Systems Business Overview
Table 92. Delcath Systems Product
Table 93. Delcath Systems Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 94. Delcath Systems Recent Development
Table 95. Eli Lilly and Company Company Details
Table 96. Eli Lilly and Company Business Overview
Table 97. Eli Lilly and Company Product
Table 98. Eli Lilly and Company Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 99. Eli Lilly and Company Recent Development
Table 100. F. Hoffman-La Roche Company Details
Table 101. F. Hoffman-La Roche Business Overview
Table 102. F. Hoffman-La Roche Product
Table 103. F. Hoffman-La Roche Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 104. F. Hoffman-La Roche Recent Development
Table 105. Fresenius Kabi Company Details
Table 106. Fresenius Kabi Business Overview
Table 107. Fresenius Kabi Product
Table 108. Fresenius Kabi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 109. Fresenius Kabi Recent Development
Table 110. Johnson & Johnson Services Business Overview
Table 111. Johnson & Johnson Services Product
Table 112. Johnson & Johnson Services Company Details
Table 113. Johnson & Johnson Services Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 114. Johnson & Johnson Services Recent Development
Table 115. Kyowa Hakko Kirin Company Details
Table 116. Kyowa Hakko Kirin Business Overview
Table 117. Kyowa Hakko Kirin Product
Table 118. Kyowa Hakko Kirin Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 119. Kyowa Hakko Kirin Recent Development
Table 120. Mylan Company Details
Table 121. Mylan Business Overview
Table 122. Mylan Product
Table 123. Mylan Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 124. Mylan Recent Development
Table 125. Novartis Company Details
Table 126. Novartis Business Overview
Table 127. Novartis Product
Table 128. Novartis Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 129. Novartis Recent Development
Table 130. Pfizer Company Details
Table 131. Pfizer Business Overview
Table 132. Pfizer Product
Table 133. Pfizer Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 134. Pfizer Recent Development
Table 135. Sanofi Company Details
Table 136. Sanofi Business Overview
Table 137. Sanofi Product
Table 138. Sanofi Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 139. Sanofi Recent Development
Table 140. Teva Pharmaceuticals Industries Company Details
Table 141. Teva Pharmaceuticals Industries Business Overview
Table 142. Teva Pharmaceuticals Industries Product
Table 143. Teva Pharmaceuticals Industries Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment Business (2015-2020) (Million US$)
Table 144. Teva Pharmaceuticals Industries Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Type: 2020 VS 2026
Figure 2. Drug Therapy Features
Figure 3. Radiation Therapy Features
Figure 4. Surgery Features
Figure 5. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Application: 2020 VS 2026
Figure 6. Intrahepatic Bile Duct Cancer Case Studies
Figure 7. Extrahepatic Bile Duct Cancer Case Studies
Figure 8. Bile Duct Cancer (Cholangiocarcinoma) Treatment Report Years Considered
Figure 9. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions: 2020 VS 2026
Figure 11. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Share by Players in 2019
Figure 14. Global Top Bile Duct Cancer (Cholangiocarcinoma) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bile Duct Cancer (Cholangiocarcinoma) Treatment as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Bile Duct Cancer (Cholangiocarcinoma) Treatment Revenue in 2019
Figure 16. North America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
胆管がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Bile Duct Cancer Drug Market The global Bile Duct Cancer Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Bile Duct Cancer Drug Scope and Market Size Bile Duct Cancer Drug marke…- 転移性がん治療の世界市場（～2026年） Metastatic breast cancer is an advanced stage of breast cancer. It involves cases in which breast cancer has spread to the other parts of the body. Some of the most common organs which are affected by metastatic breast cancer are brain, liver, bones and lungs. It is also known as stage IV breast can…
- 非血液がん治療の世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- HER2陰性乳がん治療の世界市場（～2026年） HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein. Market Analysis and Insights: Global HER2-negative breast ca…
- 小細胞肺がん治療の世界市場（～2026年） Market Analysis and Insights: Global Small Cell Lung Cancer Treatment Market The global Small Cell Lung Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Small Cell Lung Cancer Treatment Scope and Market…